Straits Times Index
3,300.04 -3.15 (-0.10%) S&P 500
5,180.74 +52.95 (+1.03%) Dow
38,852.27 +176.59 (+0.46%) Nasdaq
16,349.25 +192.92 (+1.19%) Bitcoin USD
63,999.56 +40.64 (+0.06%) CMC Crypto 200
1,326.20 -38.92 (-2.85%)
VRTX Oct 2024 420.000 call
| Previous close | 23.08 |
| Open | 23.99 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 420.00 |
| Expiry date | 2024-10-18 |
| Day's range | 23.08 - 23.99 |
| Contract range | N/A |
| Volume | |
| Open interest | 17 |
- GuruFocus.com
Vertex Pharmaceuticals Inc (VRTX) (Q1 2024) Earnings Call Transcript Highlights: Strong Growth ...
Discover how Vertex Pharmaceuticals Inc achieved significant financial and operational milestones in the first quarter of 2024.
- Reuters
UPDATE 1-Vertex tops Q1 profit estimates on robust demand for cystic fibrosis treatments
Vertex Pharmaceuticals beat Wall Street estimates for first-quarter profit on Monday, driven by robust uptake for its blockbuster cystic fibrosis treatments. Cystic fibrosis (CF) - an inherited disorder that causes severe damage to the lungs, digestive system and other organs - affects an estimated 105,000 people across 94 countries, according to data from U.S.-based CF Foundation. Vertex reported adjusted earnings per share of $4.76 on revenue of $2.69 billion, topping market estimates $4.06 on revenue of $2.58 billion, according to LSEG data, for the quarter ended March 31.
GuruFocus.comVertex Pharmaceuticals Q1 2024 Earnings: Surpasses Revenue Expectations with Strategic Expansions
Comprehensive Analysis of Vertex Pharmaceuticals' Financial Performance and Strategic Initiatives
